FDA OKs Mirdametinib for Neurofibromatosis Type 1

[ad_1]

(MedPage Today) — The FDA on Tuesday approved mirdametinib (Gomekli) for adults and kids ages 2 and up with neurofibromatosis type 1 (NF1).
Approval of the MEK inhibitor is specifically for patients who have symptomatic plexiform neurofibromas…

[ad_2]

Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/114182

Author :

Publish date : 2025-02-11 22:31:40

Copyright for syndicated content belongs to the linked Source.